>
Floating Energy Assets Explained
What if Iran's next move against Washington is not a missile launch, but a convoy of oil tankers
Artificial Intelligence Could Transform Bank Runs From Hours-Long Crises...
Dubai Just Finished the World's First Permanent Air Taxi Route: Airport to the Marina in Under 1
Doroni Aerospace Raises More than $60m for H1?X Development
After 13 Years Battling Cancer, a 61-Year-Old Brazilian Man Achieved Complete Remission...
Extraterrestrial habitats may rise via Legos of laser-fused moon dust
Battery-only 19-seater puts China in the electric airliner race
Dream Chaser space plane gets landing approval for debut mission in 2027
SpaceX Just Caught Starship on Its FIRST Attempt!
Solid-State Cells Can Make The U.S. Competitive In Batteries Again: CEO
Jetson ONE personal eVTOL pod is about to go full sky patrol
America's INSANE BREAKTHROUGH Could Replace Septic Tanks Forever

T-cell therapies for cancer—where immune cells are removed, modified and returned to the patient's blood to seek and destroy cancer cells—are the latest paradigm in cancer treatments.
The most widely-used therapy, known as CAR-T, is personalized to each patient, but it only targets a few types of cancers and has not been successful for solid tumors, which make up the vast majority of cancers.
Cardiff researchers have now discovered T-cells equipped with a new type of T-cell receptor (TCR) which recognizes and kills most human cancer types, while ignoring healthy cells.
This TCR recognizes a molecule present on the surface of a wide range of cancer cells as well as in many of the body's normal cells but, remarkably, is able to distinguish between healthy cells and cancerous ones, killing only the latter.
The researchers said this meant it offered "exciting opportunities for pan-cancer, pan-population" immunotherapies not previously thought possible.

Photo by Cardiff University
How does this new TCR work?
Conventional T-cells scan the surface of other cells to find anomalies and eliminate cancerous cells—which express abnormal proteins—but ignore cells that contain only "normal" proteins.
The scanning system recognizes small parts of cellular proteins that are bound to cell-surface molecules called human leukocyte antigen (HLA), allowing killer T-cells to see what's occurring inside cells by scanning their surface.